2-(N-t-butoxycarbonyl-N-methylamino)-4-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)aniline | 223133-34-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(N-t-butoxycarbonyl-N-methylamino)-4-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)aniline
• 英文别名: t-butyl N-[2-amino-5-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)phenyl]-N-methylcarbamate；N-(2-Amino-5-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)-phenyl)-N-methylcarbamic acid t-butyl ester；tert-butyl N-[2-amino-5-[3,5-dimethyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]phenyl]-N-methylcarbamate
• CAS: 223133-34-4
• 化学式: C₂₅H₃₅N₃O₅
• 分子量: 457.57
• InChiKey: YUXYDXGJZGODKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(N-t-butoxycarbonyl-N-methylamino)-4-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)aniline 、 4-(2,4-二氧代噻唑啉-5-基甲基)苯氧乙酸 在 氰基磷酸二乙酯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 生成 t-butyl N-[5-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)-2-[4-(2,4-dioxothiazolidin-5-ylmethyl)phenoxyacetylamino]phenyl]-N-methylcarbamate
  参考文献：
  名称：

  AMINE DERIVATIVES

  摘要：

  公开号：

  EP1167366B1
• 作为产物：
  描述：

  2-(N-t-butoxycarbonyl-N-methylamino)-4-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)nitrobenzene 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 11.0h， 以to afford the desired compound (1.56 g, Rf=0.14的产率得到2-(N-t-butoxycarbonyl-N-methylamino)-4-(4-t-butoxycarbonylamino-3,5-dimethylphenoxy)aniline
  参考文献：
  名称：

  Amine derivative compounds

  摘要：

  化合物(I)的胺类化合物的公式如下：其中R1代表可选取代的氨基甲酰基基团等，R2代表氢原子等，R3代表C1-C10烷基等，W1、W2和W3相同或不同，每个代表单键或C1-C8烷基，X、Y和Q代表硫原子等，Z代表═CH—基团等，Ar代表苯环等，L代表氢原子等，或其药学上可接受的盐。这些化合物在糖尿病、高脂血症、动脉硬化、癌症等疾病的治疗和/或预防中有用。

  公开号：

  US06562849B1

文献信息

• Substituted fused heterocyclic compound
  申请人：Sankyo Company, Limited

  公开号：US06432993B1

  公开（公告）日：2002-08-13

  Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof: wherein R1 is a group of the formula (II) or (III): R4 is a substituted phenyl or a pyridyl which may have a substituent. R5 is hydrogen or the like. R6 is hydrogen, a C1-6 alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R2 is hydrogen or the like. R3 is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C1-6 alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.

  式（I）的取代融合杂环化合物及其药学上可接受的盐： 其中R1是式（II）或（III）的基团： R4是取代苯基或可能有取代基的吡啶基。R5是氢或类似物。R6是氢、C1-6烷基或类似物。D是氧或硫。E是CH基团或氮。R2是氢或类似物。R3是2,4-二氧代噻唑啉-5-基甲基基团或类似物。A是C1-6烷基基团。B是氧或硫。这些化合物和盐可用作药物组合物的活性成分，可用于治疗患者，因为这些化合物和盐具有出色的改善胰岛素抵抗作用、抑制脂质过氧化产物生成作用、5-脂氧合酶抑制作用等。
• Alpha-substituted carboxylic acid derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030069294A1

  公开（公告）日：2003-04-10

  The &agr;-substituted carboxylic acid derivatives having the formula (I): 1 wherein R 1 is an alkyl group, etc., R 2 is a hydrogen atom, etc., R 3 is a hydrogen atom, etc., A is ═CH-group, etc., B is an oxygen atom, etc., W 1 is a C 1 -C 8 alkylene group, W 2 is a single bond or a C 1 -C 8 alkylene group, X is a hydrogen atom, etc., Y is an oxygen atom, etc., and Z 1 is an alkoxy group, etc., and pharmacologically acceptable salts, esters and amides thereof are useful for treatment and/or prevention of diabetes mellitus, impaired glucose tolerance, gestational diabetes mellitus, or the like. Some of the derivatives of the formula (I) are novel compounds.

  具有如下式(I)的α-取代羧酸衍生物，其中R1是烷基基团，R2是氢原子，R3是氢原子，A是═CH-基团，B是氧原子，W1是C1-C8烷基基团，W2是单键或C1-C8烷基基团，X是氢原子，Y是氧原子，Z1是烷氧基团，其药理学上可接受的盐、酯和酰胺对于治疗和/或预防糖尿病、糖耐量受损、妊娠期糖尿病等疾病是有用的。其中一些具有如上式(I)的衍生物是新化合物。
• Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
  申请人：Fujiwara Kosaku

  公开号：US20090028868A1

  公开（公告）日：2009-01-29

  Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I) and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).

  通过给予公式（I）的化合物和表皮生长因子受体（EGFR）抑制剂、血管内皮生长因子受体（VEGFR）抑制剂以及用于该方法的制药组合物来治疗患有癌症、肉瘤或造血系统癌症的人的方法。通过给予公式（I）的化合物来治疗胃癌、结肠癌、肺癌、乳腺癌、胰腺癌、肾癌、前列腺癌、髓母细胞瘤、横纹肌肉瘤、尤因肉瘤、脂肪肉瘤、多发性骨髓瘤和白血病的方法。
• METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG
  申请人：FUJIWARA Kosaku

  公开号：US20120258991A1

  公开（公告）日：2012-10-11

  A method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma or leukemia. An effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride is administered to a patient having said cancer.

  一种治疗乳腺癌、胰腺癌、肾癌、前列腺癌、髓母细胞瘤、横纹肌肉瘤、尤因氏肉瘤、脂肪肉瘤、多发性骨髓瘤或白血病的方法。向患有该癌症的患者给予有效量的5-(4-(6-(4-氨基-3,5-二甲基苯氧基)-1-甲基-1H-苯并咪唑-2-基甲氧基)-苄基)-噻唑烷-2,4-二酮·二盐酸盐。
• METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD
  申请人：FUJIWARA Kosaku

  公开号：US20120263716A1

  公开（公告）日：2012-10-18

  The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method.

  通过给予（a）至少一种抗癌药物，所述抗癌药物被选择自表皮生长因子受体（EGFR）抑制剂、血管内皮生长因子受体（VEGFR）抑制剂和Raf激酶抑制剂中的至少一种有效量和（b）5-（4-（6-（4-氨基-3,5-二甲基-苯氧基）-1-甲基-1H-苯并咪唑-2-基甲氧基）-苄基）-噻唑烷-2,4-二酮二盐酸盐的有效量来治疗患有癌症的人，所述癌症被选择自癌瘤、肉瘤或造血系统癌症，但当使用EGFR抑制剂Erlotinib时，所述癌症不是肺癌。本发明还提供了一种可用于实施该方法的药物组成物。